Avant Diagnostics, Inc. (AVDX) Aims to Cut Costs a
Post# of 104
Posted On: 03/02/2016 3:01:40 PM
Avant Diagnostics, Inc. (AVDX) Aims to Cut Costs and Deliver Fast Results with Ovarian Cancer Detection Test
Avant Diagnostics, Inc. (OTCQB: AVDX) is a medical technology company that focuses its efforts on the human genome project. This genetic research continues to delve deeper into identifying variations of specific genes in the genome. A genome is all of the genes that make up a cell or organism. It’s basically a recipe book on how to build a human. Variations in these genes allow scientists to see individual characteristics of disease states and a person’s propensity for them. Scientists are then able to detect diseases earlier, thereby providing early treatment, which improves a patient’s quality of life while preventing disease progression. Avant Diagnostics is a key contributor to this program by developing its own advanced technology that identifies early stage ovarian cancer. This early detection can both decrease medical costs and increase samples while producing faster results.
Avant Diagnostic’s OvaDxⓇ is a microarray-based test that measures the immune system’s response to early stage ovarian cancer tumor cells in blood samples. Impressively, this is the market’s first large panel screening test for the disease. The test has a high sensitivity for all stages of ovarian cancer and eliminates false negatives and false positives. Plus, the proteomic panel provides real-time results, speeding up the process towards treatment if necessary.
To further stand by its aim of creating testing with fast results, Avant Diagnostics will soon merge with Amarantus Diagnostics, a biotechnology firm that develops diagnostic tests for neurological diseases. This partnership has a high potential of delivering diagnosis and monitoring tools for early detection at an even faster rate.
Not only does OvaDxⓇ deliver fast results, but it cuts costs in the overall treatment of ovarian cancer for patients and health centers. According to Current Women’s Health Reviews, late-stage ovarian cancer treatment could cost at least $210,000 or more. With early detection, a patient can get affordable treatment for the disease that has not progressed as far as it could.
Avant Diagnostics intends to make its product available as soon as possible, so women can be aware of their own ovarian cancer risks. With accurate and fast results, the company offers women the chance at early treatment to prevent expensive costs and painful therapy down the road.
For more information, visit the company website at www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Avant Diagnostics, Inc. (OTCQB: AVDX) is a medical technology company that focuses its efforts on the human genome project. This genetic research continues to delve deeper into identifying variations of specific genes in the genome. A genome is all of the genes that make up a cell or organism. It’s basically a recipe book on how to build a human. Variations in these genes allow scientists to see individual characteristics of disease states and a person’s propensity for them. Scientists are then able to detect diseases earlier, thereby providing early treatment, which improves a patient’s quality of life while preventing disease progression. Avant Diagnostics is a key contributor to this program by developing its own advanced technology that identifies early stage ovarian cancer. This early detection can both decrease medical costs and increase samples while producing faster results.
Avant Diagnostic’s OvaDxⓇ is a microarray-based test that measures the immune system’s response to early stage ovarian cancer tumor cells in blood samples. Impressively, this is the market’s first large panel screening test for the disease. The test has a high sensitivity for all stages of ovarian cancer and eliminates false negatives and false positives. Plus, the proteomic panel provides real-time results, speeding up the process towards treatment if necessary.
To further stand by its aim of creating testing with fast results, Avant Diagnostics will soon merge with Amarantus Diagnostics, a biotechnology firm that develops diagnostic tests for neurological diseases. This partnership has a high potential of delivering diagnosis and monitoring tools for early detection at an even faster rate.
Not only does OvaDxⓇ deliver fast results, but it cuts costs in the overall treatment of ovarian cancer for patients and health centers. According to Current Women’s Health Reviews, late-stage ovarian cancer treatment could cost at least $210,000 or more. With early detection, a patient can get affordable treatment for the disease that has not progressed as far as it could.
Avant Diagnostics intends to make its product available as soon as possible, so women can be aware of their own ovarian cancer risks. With accurate and fast results, the company offers women the chance at early treatment to prevent expensive costs and painful therapy down the road.
For more information, visit the company website at www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Avant Diagnostics, Inc. (AVDX) Stock Research Links
Scroll down for more posts ▼